Enovis Corporation (NYSE: ENOV) is a Healthcare company (Medical - Devices) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Enovis Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $27.22, Enovis Corporation trades at 0.7x sales and 1.1x book value. Over the last twelve months it generated about $2.3B of revenue and a net loss of $529M. It runs a gross margin of 59.5%, an operating margin of 3.9% and a net margin of -22.9%. It shows return on equity of -35.5%, return on invested capital of 2.8% and a free cash flow yield of 4.4%. On the balance sheet: a debt-to-equity ratio of 0.90 and a current ratio of 2.15. Over the past 52 weeks the share price ranged from $16.70 to $31.67, with a beta of 1.42.
Enovis Corporation does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 12 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of October 2026, Enovis Corporation (ENOV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 101.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.27% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 101.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.27% / 33% · Receivables / Mkt Cap (36m) 34.5% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 101.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.27% / 33.33% · Receivables / Mkt Cap (24m) 34.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 34.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 0.97% / 33.33% · Receivables / Avg Assets (4Q) 11.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 33.7% / 33.33% · (Cash+ST Inv) / Total Assets 1.75% / 33.33% · (Cash+Recv) / Total Assets 13.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of October 2026, Enovis Corporation (ENOV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Enovis Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
Enovis Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated October 2, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.